ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma

Cancer Research and Treatment

Volumn 45, Issue 1, 2013, Pages 63-69

  Park, Kyun Woo ^a   Jung, Eun Seon ^a   Kim, Dong Gu ^a   Yoo, Young Kyung ^a   Hong, Tae Ho ^a   Lee, In Seok ^a   Koh, Yoon Ho ^b   Kim, Ji Hoon ^c   Lee, Myung Ah ^a  

^a The Catholic University of Korea   (South Korea)

^b Uijeongbu St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Bile duct neoplasms; ERCC1; Prognosis

Indexed keywords

CISPLATIN; CYCLIN D1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; PROTEIN P53; SURVIVIN; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERINEURAL INVASION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; VEIN;

EID: 84879074132     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.45.1.63     Document Type: Article

References (24)

1. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45:856-67.
2. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer. 2001;92:2374-83.
3. Weber A, Landrock S, Schneider J, Stangl M, Neu B, Born P, et al. Longterm outcome and prognostic factors of patients with hilar cholangiocarcinoma. World J Gastroenterol. 2007;13:1422-6.
4. Sano T, Shimada K, Sakamoto Y, Ojima H, Esaki M, Kosuge T. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann Surg Oncol. 2008;15:590-9.
5. Aishima S, Kuroda Y, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol. 2007;31:1059-67.
6. Hong SM, Hwang I, Song DE, Choi J, Yu E. Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Mod Pathol. 2007;20:562-9.
7. Arora DS, Ramsdale J, Lodge JP, Wyatt JI. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases. Histopathology. 1999;34:497-501.
8. Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8:3156-63.
9. Thanasai J, Limpaiboon T, Jearanaikoon P, Sripa B, Pairojkul C, Tantimavanich S, et al. Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. World J Gastroenterol. 2010;16:1631-8.
10. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463-73.
11. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol. 2009;15:4240-62.
12. Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol. 2012;18:2591-6.
13. Shirai K, Ebata T, Oda K, Nishio H, Nagasaka T, Nimura Y, et al. Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2008;32:2395-402.
14. Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg. 2002;26:687-93.
15. Tajima Y, Kuroki T, Fukuda K, Tsuneoka N, Furui J, Kanematsu T. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg. 2004;91:99-104.
16. Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, Belghiti J, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009;51:93-101.
17. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multiinstitutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140-5.
18. Kim WB, Han HJ, Lee HJ, Park SS, Song TJ, Kim HK, et al. Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer. Ann Surg Oncol. 2009;16:23-34.
19. Wang J, Wang X, Xie S, Yan Z, Li Z, Li Y, et al. p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies. Dig Dis Sci. 2011;56:655-62.
20. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 2006;24:1152-60.
21. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33:565-77.
22. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005;6:158-66.
23. Aishima S, Taguchi K, Sugimachi K, Asayama Y, Nishi H, Shimada M, et al. The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma. Int J Surg Pathol. 2002;10:47-56.
24. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology. 2004;51:1653-7.